Virbac Posts Strong H1 2026 Growth on Supercharge Platforms
Event summary
- H1 2026 revenue reached €768m, up +7.4% at CERS vs H1 2025 (+4.0% actual)
- Companion animal segment grew +10.0%, farm animal +6.7%
- Supercharge platforms (excl. Thyronorm) increased ~+12% at CERS
- Thyronorm acquisition contributed 1.4 percentage points to growth
- Full-year guidance confirmed at upper end: 5.5%-7.5% revenue growth, ~17% operating margin
The big picture
Virbac's H1 performance highlights the resilience of animal healthcare demand despite macroeconomic challenges. The company's strategic focus on high-growth Supercharge platforms and targeted acquisitions like Thyronorm positions it well in a consolidating veterinary market. With €768m in first-half revenue, Virbac is outperforming many peers in organic growth while navigating currency headwinds.
What we're watching
- Geographic Expansion
- How Virbac will sustain North American growth despite temporary manufacturing challenges...
- Integration Success
- Whether Thyronorm acquisition will continue delivering commercial synergies across continents...
- Pricing Strategy
- The pace at which Virbac can maintain ~+2% price increases amid economic headwinds...